We are live on ! Find out more
OPPM

Opus Point Partners Management Portfolio holdings

AUM $55.3M
1-Year Est. Return 7.48%
This Fund
S&P 500
This Quarter Est. Return
+11.44%
1 Year Est. Return
-7.48%
3 Year Est. Return
+85.18%
5 Year Est. Return
+168.21%
10 Year Est. Return
–
AUM
$46.1M
AUM Growth
-$4.88M
Cap. Flow
-$2.83M
Cap. Flow %
-6.15%
Top 10 Hldgs %
52.4%
Holding
53
New
2
Increased
15
Reduced
16
Closed
3

Top Buys

Rank Stock Value
1
XBI icon
State Street SPDR S&P Biotech ETF
XBI
+$3.14M
2
LITS
Lite Strategy Inc
LITS
+$1.23M
3
EXEL icon
Exelixis
EXEL
+$280K
4
INCY icon
Incyte
INCY
+$71.3K
5
ALKS icon
Alkermes
ALKS
+$55.5K

Top Sells

Rank Stock Value
1
BIB icon
ProShares Ultra NASDAQ Biotechnology
BIB
+$5.11M
2
NKTR icon
Nektar Therapeutics
NKTR
+$1.15M
3
KPTI icon
Karyopharm Therapeutics
KPTI
+$671K
4
ACAD icon
Acadia Pharmaceuticals
ACAD
+$382K
5
AVXS
AveXis, Inc. Common Stock
AVXS
+$281K

Sector Composition

Rank Sector Weight
1 Healthcare 71.92%
2 Miscellaneous 28.08%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
XBI icon
1
State Street SPDR S&P Biotech ETF
XBI
$11.7B
$5.52M 11.97%
58,000
+34,200
+144% +$3.14M
BIB icon
2
ProShares Ultra NASDAQ Biotechnology
BIB
$105M
$5.37M 11.64%
93,805
-93,805
-50% -$5.11M
MTD icon
3
Mettler-Toledo International
MTD
$28.2B
$2.08M 4.51%
3,594
– –
IBB icon
4
iShares Biotechnology ETF
IBB
$10.8B
$2.06M 4.47%
18,750
– –
ALXN
5
DELISTED
Alexion Pharmaceuticals
ALXN
$1.71M 3.7%
13,734
-119
-0.9% -$13.9K
VRTX icon
6
Vertex Pharmaceuticals
VRTX
$139B
$1.59M 3.44%
9,331
+107
+1% +$16.6K
LITS
7
Lite Strategy Inc
LITS
$34M
$1.58M 3.42%
+20,000
New +$1.23M
ILMN icon
8
Illumina
ILMN
$34.4B
$1.5M 3.24%
5,502
-158
-3% -$40.2K
ALNY icon
9
Alnylam Pharmaceuticals
ALNY
$31.7B
$1.39M 3.01%
14,112
+432
+3% +$42.8K
SGEN
10
DELISTED
Seagen Inc. Common Stock
SGEN
$1.38M 3%
20,834
-292
-1% -$16.7K
AGIO icon
11
Agios Pharmaceuticals
AGIO
$2.05B
$1.33M 2.89%
15,833
-169
-1% -$14.7K
LOXO
12
DELISTED
Loxo Oncology, Inc
LOXO
$1.2M 2.6%
6,900
– –
QGEN icon
13
Qiagen
QGEN
$9.03B
$1.18M 2.57%
30,857
-419
-1% -$15.4K
KYNB
14
Kyntra Bio
KYNB
$32.4M
$1.15M 2.5%
737
+6
+0.8% +$7.82K
PRQR icon
15
ProQR Therapeutics
PRQR
$327M
$1.12M 2.44%
153,846
– –
AMGN icon
16
Amgen
AMGN
$236B
$1.09M 2.37%
5,930
+125
+2% +$22.1K
ALKS icon
17
Alkermes
ALKS
$8.2B
$1.05M 2.28%
25,552
+1,219
+5% +$55.5K
BIIB icon
18
Biogen
BIIB
$32.7B
$1.02M 2.22%
3,532
+15
+0.4% +$4.22K
IONS icon
19
Ionis Pharmaceuticals
IONS
$10.4B
$997K 2.16%
23,916
+783
+3% +$34.7K
BMRN icon
20
BioMarin Pharmaceuticals
BMRN
$12.6B
$974K 2.11%
10,336
-320
-3% -$28K
REGN icon
21
Regeneron Pharmaceuticals
REGN
$83.2B
$931K 2.02%
2,698
+76
+3% +$23.8K
INCY icon
22
Incyte
INCY
$25.9B
$826K 1.79%
12,321
+1,043
+9% +$71.3K
CELG
23
DELISTED
Celgene Corp
CELG
$772K 1.67%
9,724
+212
+2% +$17.6K
CLVS
24
DELISTED
Clovis Oncology, Inc.
CLVS
$591K 1.28%
13,000
– –
TSRO
25
DELISTED
TESARO, Inc.
TSRO
$511K 1.11%
11,500
– –
1
2 3

Similar funds

KIA
Kopp Investment Advisors Bloomington, Minnesota $54.4M AUM 14.33% 1-Year Est. Return
PGA
Premia Global Advisors Coral Gables, Florida $57.9M AUM 2.91% 1-Year Est. Return
GX
Greylock XII Menlo Park, California $51.9M AUM 11.52% 1-Year Est. Return
SCG
Saban Capital Group Los Angeles, California $59.5M AUM 3.83% 1-Year Est. Return
TCMV
Technology Crossover Management VI Menlo Park, California $59.6M AUM 18.81% 1-Year Est. Return
FCM
Farmstead Capital Management Ridgewood, New Jersey $49M AUM 10.57% 1-Year Est. Return
DP
DW Partners New York $62.3M AUM 25.52% 1-Year Est. Return
SAM
Sheffield Asset Management Chicago, Illinois $48.1M AUM 12.96% 1-Year Est. Return

Opus Point Partners Management's Q2 2018 Portfolio in Review

As of Q2 2018, Opus Point Partners Management held 53 positions worth $46.1M, down 9.6% from $51M the previous quarter. Its ten largest holdings account for 52% of the portfolio.

Opus Point Partners Management withdrew a net $2.83M in Q2 2018, closing 3 positions and reducing 16 holdings. Its most notable exit was Karyopharm Therapeutics, an estimated $671K position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 72% of assets, up from 65% a quarter earlier, followed by Miscellaneous.

Against the trend, Opus Point Partners Management opened a new position in Lite Strategy Inc worth $1.58M.

  • Opus Point Partners Management's largest Q2 2018 buy was Lite Strategy Inc: 20,000 shares worth $1.58M.
  • Opus Point Partners Management added most to State Street SPDR S&P Biotech ETF in Q2 2018, an estimated $3.14M increase.
  • Opus Point Partners Management's biggest Q2 2018 reduction was ProShares Ultra NASDAQ Biotechnology, cutting an estimated $5.11M.
  • Opus Point Partners Management fully exited Karyopharm Therapeutics in Q2 2018, selling an estimated $671K.
  • Opus Point Partners Management's ten largest holdings make up 52% of its $46.1M portfolio in Q2 2018.
  • Opus Point Partners Management opened 2 new positions and closed 3 in Q2 2018.
  • Opus Point Partners Management's portfolio value fell 9.6% quarter-over-quarter to $46.1M.

Based on Opus Point Partners Management's 13F filing for Q2 2018, filed 14 Aug 2018.